Organigram Global (OGI) Non Operating Investment Income (2018 - 2026)
Organigram Global (OGI) posted quarterly Non Operating Investment Income of -$28.4 million for Q1 2026, up 13.65% year-over-year from -$25.0 million in Q1 2025, and down 62.24% quarter-over-quarter from -$17.5 million in Q4 2025.
Organigram Global (OGI) Non Operating Investment Income (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Non Operating Investment Income for 6 consecutive years, with -$28.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income rose 13.65% year-over-year to -$28.4 million; the TTM figure through Mar 2026 stood at -$68.4 million (down 448.79% YoY), while the FY2025 annual figure was -$6539.7, down 101.41% from the prior year.
- Non Operating Investment Income retreated to -$28.4 million in Q1 2026 per OGI's latest filing, from -$17.5 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $10.4 million in Q4 2024 and bottomed at -$32.9 million in Q1 2025.
- Historically, Non Operating Investment Income has averaged -$13.6 million across 4 years, with a median of -$17.5 million in 2025.
- Annual changes were most pronounced in 2025 — Non Operating Investment Income plunged 268.57% — and 2026, when it climbed 13.65%.
- Organigram Global's Non Operating Investment Income stood at $237951.8 in 2023, then jumped by 4260.64% to $10.4 million in 2024, then slumped by 268.57% to -$17.5 million in 2025, then plunged by 62.24% to -$28.4 million in 2026.
- Business Quant data shows OGI's Non Operating Investment Income at -$28.4 million in Q1 2026, -$17.5 million in Q4 2025, and -$32.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Organigram Global | 152.57 Mn | 152.45 Mn | 28.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.38 Mn |
| Mar 31, 2026 | -28.38 Mn |
| Dec 31, 2025 | -17.49 Mn |
| Dec 31, 2025 | -17.49 Mn |
| Mar 31, 2025 | -32.86 Mn |
| Mar 31, 2025 | -32.86 Mn |
| Dec 31, 2024 | 10.38 Mn |
| Dec 31, 2024 | 10.38 Mn |
| Sep 30, 2023 | 237,951.82 |
| Sep 30, 2023 | 237,951.82 |
| Feb 28, 2021 | 42.33 Mn |
| Feb 28, 2021 | 42.33 Mn |
| Nov 30, 2018 | -246,000.00 |
| Nov 30, 2018 | -246,000.00 |